Sign In
Buy REGN
$628.73
+9.78 (+1.58%)
At Close: Jun 04, 2026
Compared to Estimates, Regeneron (REGN) Q4 Earnings: A Look at Key Metrics
05:45pm, Friday, 03'rd Feb 2023 Zacks Investment Research
While the top- and bottom-line numbers for Regeneron (REGN) give a sense of how the business performed in the quarter ended December 2022, it could be worth looking at how some of its key metrics comp
Regeneron (REGN) Q4 Earnings & Sales Beat, Eylea Sales Decline
04:35pm, Friday, 03'rd Feb 2023 Zacks Investment Research
Regeneron (REGN) tops earnings and sales estimates for the fourth quarter. However, sales of the lead drug Eylea decline year over year.
Drug, Chip Stocks Hit 52-Week Highs As One Breaks Out Of Bullish Chart Pattern
04:20pm, Friday, 03'rd Feb 2023
Regeneron and Analog Devices hit new highs and break out. REGN had strong fourth quarter earnings.
Sanofi (SNY) Q4 Earnings Miss Estimates, Vaccine Sales Weak
02:55pm, Friday, 03'rd Feb 2023 Zacks Investment Research
Sanofi (SNY) misses fourth-quarter estimates for earnings and sales. Higher sales of Dupixent and other specialty medicines were offset by a decline in vaccine sales.
Compared to Estimates, Regeneron (REGN) Q4 Earnings: A Look at Key Metrics
02:18pm, Friday, 03'rd Feb 2023
While the top- and bottom-line numbers for Regeneron (REGN) give a sense of how the business performed in the quarter ended December 2022, it could be worth looking at how some of its key metrics comp
Regeneron (REGN) Q4 Earnings & Sales Beat, Eylea Sales Decline
12:48pm, Friday, 03'rd Feb 2023
Regeneron (REGN) tops earnings and sales estimates for the fourth quarter. However, sales of the lead drug Eylea decline year over year.
Regeneron (REGN) Q4 Earnings and Revenues Beat Estimates
12:45pm, Friday, 03'rd Feb 2023 Zacks Investment Research
Regeneron (REGN) delivered earnings and revenue surprises of 29.75% and 7.84%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Regeneron Pharmaceuticals, Inc. (REGN) Q4 2022 Earnings Call Transcript
12:43pm, Friday, 03'rd Feb 2023
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN ) Q4 2022 Earnings Conference Call February 3, 2023 8:30 AM ET Company Participants Ryan Crowe - Vice President, Investor Relations Leonard Schleifer - Co-
Nasdaq Futures Deflate As Apple Leads Tech Disappointments: Traders Look To Jobs Data For Mitigating Impact
12:00pm, Friday, 03'rd Feb 2023 Benzinga
Trading in the U.S. index futures suggests stocks may end a solidly positive week on a negative note. That said, the data-dependency of the Fed places the onus of providing trading cues to each incomi
Regeneron Pharma Outplays Fourth-Quarter Decline, But Sanofi Stock Topples
09:02am, Friday, 03'rd Feb 2023
Regeneron Pharma beat quarterly forecasts Friday, but its partner Sanofi posted a mixed report. Regeneron stock rose as SNY stock toppled.
Regeneron (REGN) Q4 Earnings and Revenues Beat Estimates
09:02am, Friday, 03'rd Feb 2023
Regeneron (REGN) delivered earnings and revenue surprises of 29.75% and 7.84%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Regeneron stock rallies after profit and revenue beat expectations by wide margins
06:45am, Friday, 03'rd Feb 2023
Shares of Regeneron Pharmaceuticals Inc. REGN, -0.90% rallied 1.9% toward a two-month high in premarket trading Friday, after the biotechnology company reported fourth-quarter profit and revenue that
The 7 Most Undervalued Stocks to Buy in February 2023
03:19pm, Thursday, 02'nd Feb 2023
As Feb. gets underway, I'm finding under-appreciated, undervalued stocks to buy. When seeking value in the stock market the hope is that other investors will see what you see: The underappreciated va
The 7 Most Undervalued Biotech Stocks to Buy in February 2023
02:19pm, Thursday, 02'nd Feb 2023
You don't have to be particularly astute to recognize the importance of the most undervalued biotech stocks to buy. Fundamentally, the enterprises that undergird these names operate on the cutting edg
Why Regeneron (REGN) Might Surprise This Earnings Season
09:47am, Thursday, 02'nd Feb 2023
Regeneron (REGN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
